Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591551 · ClinicalTrials.gov registry record · Phase 4
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
A Phase 4 study, sponsored by Cornerstone Health Care, PA.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT01591551 is a Phase 4 study that has completed, run by Cornerstone Health Care, PA. The registered enrollment target is 37 participants.
The verdict
NCT01591551, a Phase 4 study, has completed, sponsored by Cornerstone Health Care, PA.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving Natalizumab for 6 months relative to baseline.
Interventions
- DRUG Natalizumab (Tysabri)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591551
The ClinicalTrials.gov registry entry for NCT01591551 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cornerstone Health Care, PA, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Natalizumab (Tysabri) is the first listed.
NCT01591551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01591551 about?
NCT01591551 is a clinical study titled "NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness". The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving Natalizumab for 6 months relative to baseline.
What is the current status of trial NCT01591551?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2012-03. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01591551?
The interventions under investigation include: Natalizumab (Tysabri) (DRUG).
Who is sponsoring clinical trial NCT01591551?
This trial is sponsored by Cornerstone Health Care, PA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.